Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.

Chung, Hyun Cheol; Kok, Victor C; Cheng, Rebecca; Hsu, Yanzhi; Orlando, Mauro; Fuchs, Charles; Cho, Jae Yong

Chung, Hyun Cheol; Kok, Victor C; Cheng, Rebecca; Hsu, Yanzhi; Orlando, Mauro; Fuchs, Charles; Cho, Jae Yong.

Affiliation

Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kok VC; Division of Medical Oncology, Department of Internal Medicine, Kuang Tien General Hospital, Taichung, Taiwan.
Cheng R; Eli Lilly and Company, Taipei, Taiwan.
Hsu Y; Eli Lilly and Company, Indianapolis, IN, USA.
Orlando M; Eli Lilly and Company, Buenos Aires, Argentina.
Fuchs C; Yale Cancer Center, New Haven, CT, USA.
Cho JY; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Asia Pac J Clin Oncol ; 14(3): 204-209, 2018 Jun.

Article in En | MEDLINE | ID: mdl-29318751

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Stomach Neoplasms/drug therapy; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacology; Asian People; Female; Humans; Male; Middle Aged; Stomach Neoplasms/ethnology; Stomach Neoplasms/pathology; Survival Analysis; Treatment Outcome; Ramucirumab

Key words

Asia; gastric cancer; gastrointestinal neoplasms; ramucirumab; vascular endothelial growth factor receptor-2

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Asia Pac J Clin Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google